tapebrief
AMCR · Q2 2026

AMCR · Q3 2026 Earnings

Cautious

Amcor

Reported May 6, 2026

30-second summary

Amcor printed Q3 adjusted EPS of $0.96 against the $0.90–1.00 guide and $77M of synergies against the $70–80M frame — both squarely on plan — but cut FY26 adjusted EPS to $3.98–$4.03 from $4.00–$4.15 (-1.7% at midpoint) and FY26 FCF to $1.5–$1.6B from $1.8–$1.9B (-$300M / -16.2% at midpoint). The +12–17% constant-currency EPS growth range from prior quarters collapsed to "approximately 12% at the midpoint," eliminating the upside scenario entirely. Q3 execution was in line; the FY frame around it deteriorated, with management blaming Middle East-driven resin volatility and an explicit decision to hold elevated inventory through Q4 to protect customer supply.

Headline numbers

EPS

Q3 FY2026

$0.96

Revenue

Q3 FY2026

$5.91B

+77.0% YoY

Gross margin

Q3 FY2026

20.1%

Free cash flow

Q3 FY2026

$-0.04B

Operating margin

Q3 FY2026

7.8%

Key financials

Q3 FY2026
MetricQ3 FY2026YoYQ2 FY2026QoQ
Revenue$5.91B+77.0%$5.45B+8.5%
EPS$0.96—$0.86+11.6%
Gross margin20.1%—19.1%+100bps
Operating margin7.8%—6.1%+170bps
Free cash flow$-0.04B—$0.29B-113.5%

Guidance

Company lowered full-year FY2026 adjusted EPS and free cash flow guidance, narrowing growth expectations to approximately 12% at the midpoint while raising Berry acquisition synergy realizations.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Adjusted EPS
FY 2026
$4.00 to $4.15$3.98 to $4.03-0.12 to -0.12 (midpoint lowered by $0.045)Lowered
Free Cash Flow
FY 2026
$1.8 to $1.9 billion$1.5 to $1.6 billion-$0.30 to -0.30 billion (midpoint lowered by $0.25B)Lowered
Adjusted EPS growth
FY 2026
12% to 17% constant currency growthapproximately 12% at the midpointUpper end of range narrowed from 17% to ~12%; range collapsed to point estimateLowered
Synergy benefits related to Berry acquisition
FY 2026
at least $260 million pre-tax$270 million+$10 million (vs. minimum threshold)Raised

Segment KPIs

Q3 FY2026
SegmentQ3 FY2026YoY
Global Flexible Packaging Solutions$3.25B+29.0%
Global Rigid Packaging Solutions$2.664B+174.0%

Other KPIs

Q3 FY2026
SegmentQ3 FY2026
Adjusted EBITDA$892 million
Adjusted EBITDA Margin15.1%
Adjusted EBIT$687 million
Adjusted EBIT Margin11.6%
Acquisition Synergies Realized$77 million
Organic Volume Growth-1%
Net Debt$14,266 million
Adjusted EPS Guidance (FY2026)$3.98 to $4.03

Management tone

Q4 stabilization-and-pruning → Q1 synergy overdelivery and macro decoupling → Q2 quantified back-half EBIT bridge → Q3 working capital trade-off and guide cuts.

The "we don't need the macro" framing from Q1 has been replaced by "we are managing through resin volatility and accepting cash flow cost to do it." In Q1 management said the +12–17% EPS growth target was "not dependent on improvements in the macroeconomic environment." This quarter that range collapsed to "approximately 12% at the midpoint" and the FCF guide was cut $300M, with PK framing the decision as: "continuity of supply is a critical priority for our customers, and to meet that need, we have made choices about working capital management, primarily inventory, through the fourth quarter." The macro is no longer decoupled — it is being absorbed via the balance sheet rather than the P&L.

The Middle East risk language was introduced and immediately neutralized in the same breath — a posture that reads as both confident and defensive. PK: "we do not expect the current conflict in the Middle East to have a material impact on Q4 earnings" and "we have no operations in and minimal polymer sourcing from the region." The Q4 FY25 call had no Middle East mention; Q1 had no Middle East mention; Q2 had no Middle East mention. This quarter the topic appears with a fully formed mitigation narrative including <5% resin sourcing from the region and 65% from North America. That is the kind of pre-rebuttal that gets prepared when management knows the question is coming — defensible on substance, but the introduction of the topic at all is a tonal break from three consecutive quarters of silence.

Synergy execution remains the one part of the narrative that consistently overdelivers and management has stopped hedging it. Q4 FY25: "approximately $260M." Q1: "at least $260M." Q2: "at least $260M" reaffirmed. Q3: hard commit to $270M. PK: "we will deliver $270 million of synergies in fiscal 2026 ahead of our initial $260 million year one target." This is the only line where the language has progressively firmed rather than softened, and it is also the only positive guidance revision on the print.

The volume framing arc has now fully cycled from optimism to managed decline to selective outperformance. Q1 floated positive back-half volumes. Q2 walked that back to -1.5% through H2. Q3 came in at -1.5% with management pointing to the six focus categories (50% of core) running flat to low-mid single digits up. The aggregate number is still negative; the framing has shifted to "the parts of the portfolio we care about are working."

Recurring themes management leaned on this quarter:

Supply chain resilience as competitive advantage amid geopolitical disruptionSynergy acceleration exceeding initial targets with strong procurement and G&A capturePortfolio optimization via divestitures ($500M combined value) sharpening focus on high-return core portfolioDisciplined pricing and cost actions offsetting unprecedented resin inflationWorking capital/inventory strategy trade-off: accepting near-term free cash flow reduction to maintain supply continuityFiscal year calendar shift to December 31 effective 2027 and Miami headquarters relocation

Risks management surfaced:

Middle East geopolitical conflict creating resin supply volatility and inflation (partially mitigated)Volume declines in developed markets (North America/Europe low single-digit weakness) amid consumer stretchWinter storm impacts in January-February affecting U.S. production ($25M unfavorable EBIT impact)Inflation significantly exceeding historical norms requiring accelerated pricing actions and customer negotiationLeverage temporarily elevated above target range (3.4-3.5x vs. target 2.5-3x) due to working capital/volume impacts

Q&A highlights

Hillary Coconato · Deutsche Bank

Can you provide recent examples of growth synergies from combined AMCO and BERI products, specifically winning new contracts using integrated offerings?

Management highlighted $100 million in annualized closed deals year-to-date, tracking ahead of the $280 million three-year target at $110 million. Key example: a global pharma customer for GLP-1 oral solid dose drugs requiring different packaging formats for Europe (blister) and North America (rigid container), which only the combined entity could serve. Growth synergies driven by selling systems rather than components, leveraging complementary technology footprints and additional capacity.

$100 million annualized synergy deals closed year-to-date$110 million total synergies captured (vs. $280 million three-year target)Synergies began impacting bottom line in Q3 with 'a couple of million'Global pharma GLP-1 contract win across Europe and North America

Gabe Hyde · Wells Fargo Securities

Can you comment on healthcare and nutrition being called out as weakness areas, and specifically healthcare's expected improvement beginning mid-2026?

Management clarified that six focus categories (50% of business) outperformed overall core business with flat to low-single-digit growth despite overall company being down 1.5%. Five of six focus categories were flat to low-mid single digits up. Healthcare had slightly down volumes but good positive mix. Q3 positives included pharma customer wins, sustainability partnership with generics player, and new Malaysia coding facility with air knife technology. Volume weakness attributed to U.S. winter storm impacts and weaker cold/flu season. Nutrition weakness was concentrated in discretionary categories outside focus areas.

Six focus categories flat to low-mid single digits up (vs. 1.5% company decline)Five of six focus categories either flat or positiveHealthcare volumes slightly down but with positive mixNew Malaysia coding facility opened April with air knife technology

Answers to last quarter's watch list

Q3 EPS against the $0.90–1.00 guide and synergies against $70–80M — EPS landed at $0.96 (mid-upper of range) and synergies at $77M (mid-upper of range). Both metrics hit the explicit Q2 commitments, removing the "first execution miss since deal close" risk. However, the FY guide was cut on the same print, so the read-through is that Q3 execution met the bar while management lost confidence in Q4. Status: Resolved positively (on Q3 specifically; FY frame moved against the bull)
Reinstatement of capex, interest, and tax rate guides — Capex was reaffirmed at $850–$900M; net interest and tax rate guides remain withdrawn for a third consecutive quarter. Combined with the EPS and FCF cuts this quarter, continued silence on the remaining line-item assumptions reads as a partial disclosure regression rather than full reinstatement. Status: Partially resolved
Non-core EBIT margin recovery from ~3% in Q2 toward 7–8% H2 frame — Management stated North American beverage Q3 EBIT was "in line with prior year" with margins meeting expectations, and that sequential improvement is expected in Q4. No explicit Q3 non-core margin figure was disclosed. The qualitative framing suggests the recovery is on track, but the absence of a hard number leaves the $30–50M FY EPS risk flagged last quarter only partially resolved.
Continue monitoring
North American beverage strategic update — Seventh consecutive quarter without a process announcement, write-down, or explicit retain-and-transform commitment. Management said "encouraging conversations" are underway on the sale process and that the non-core perimeter is unchanged. Closer to a process than a year ago, but still no hard milestone.
Continue monitoring
H2 FCF inflection magnitude — Q3 FCF was $(39)M against the $700–800M bar flagged last quarter. With YTD FCF at -$93M, Q4 alone must generate ~$1.6B to hit the new $1.5–$1.6B FY guide (which itself is $300M below the prior $1.8–$1.9B frame). The inflection did not happen in Q3; management cut the FY guide rather than insist on it.
Resolved negatively

What to watch into next quarter

Q4 FCF print against the implied ~$1.6B step-up: With YTD FCF at -$93M and the new FY guide at $1.5–$1.6B, Q4 carries essentially the entire FY cash generation. A Q4 FCF print below $1.5B forces a second FCF cut or full-year miss against a guide that was just lowered.

Q4 synergy capture of ~$100M to deliver the $270M FY frame: Q3 ran at $77M; Q4 needs to step up roughly 30% sequentially. A print below $90M would put the only line management has firmed at risk.

Whether the transition period setup acknowledges inventory unwind: The $300M FCF cut was framed as a Q4 working-capital decision. If the July–December 2026 transition period guidance (introduced at the Q4 print) does not include an explicit inventory release contributing to FCF, the cash flow loss should be treated as permanent rather than timing.

Resin cost pass-through cadence: Management cited resin inflation "significantly exceeding historical norms" requiring accelerated pricing. Watch Q4 margin progression for whether pricing actions are catching up to input costs or whether the gap widens.

North American beverage process milestone: "Encouraging conversations" is now in its second quarter as the operative phrase. Any concrete movement — signed LOI, announced buyer process, or write-down — closes a structural question that has now spanned the entire combined-entity reporting history.

Reinstatement of net interest and tax rate guides at Q4: Capex was reaffirmed this quarter; net interest and tax rate remain absent. Continued silence at Q4 alongside the headline EPS and FCF cuts hardens it from transitional to structural.

Sources

  1. Amcor Q3 FY2026 press release (SEC filing): https://www.sec.gov/Archives/edgar/data/1748790/000174879026000014/exhibit991q32026.htm
  2. Amcor Q3 FY2026 earnings call Q&A (analyst exchanges with Deutsche Bank, Wells Fargo Securities).
  3. Amcor Q2 FY2026 brief (tapebrief prior coverage, for trend context).
  4. Amcor Q1 FY2026 brief (tapebrief prior coverage, for trend context).
  5. Amcor Q4 FY2025 brief (tapebrief prior coverage, for trend context).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.